Dietary treatments and new therapeutic perspective in GLUT1 deficiency syndrome

Pierangelo Veggiotti, Valentina De Giorgis

Research output: Contribution to journalArticle

Abstract

GLUT1 deficiency syndrome (GLUT1DS) results from impaired glucose transport into the brain: awareness of its wide phenotypic spectrum is a prerequisite in order to ensure an early diagnosis, treating the patients is the subsequent challenge to allow prompt compensation for the brain's lack of fuel. The ketogenic diet (KD) plays a primary role in the treatment of GLUT1DS because it provides ketone bodies as an alternative source to meet the demands of energy of the brain. Therefore, we recommend early initiation of the KD based on the assumption that early diagnosis and treatment improves the long term neurological outcome: the classic KD (4:1 or 3:1) at the present time is the most proven and effective in GLUT1DS. A KD should be continued at least until adolescence, although there are reports of good tolerability even in adulthood, possibly with a less rigorous ratio; in our experience seizure and movement disorder control can be achieved by a 2:1 ketogenic ratio but the relationship between ketosis and neurodevelopmental outcome remains undetermined. Other types of KDs can, therefore, be considered. The Modified Atkins diet, for example, is also well tolerated and provides effective symptom control; furthermore, this diet has the advantage of being easy to prepare and more palatable, which are important requirements for good compliance. Nevertheless, about 20 % of these patients have compliance trouble or the same diet loses its effectiveness over time; for these reasons, new therapeutic strategies are currently under investigation but further studies on pathophysiological mechanisms and potential effects of novel "diets" or "therapies" are needed for this new pathology.

Original languageEnglish
JournalCurrent Treatment Options in Neurology
Volume16
Issue number5
DOIs
Publication statusPublished - 2014

Fingerprint

Ketogenic Diet
Early Diagnosis
Brain
Carbohydrate-Restricted Diet
Diet
Diet Therapy
Ketone Bodies
Ketosis
Movement Disorders
Therapeutics
Patient Compliance
Epilepsy
Pathology
Glucose
Glut1 Deficiency Syndrome

Keywords

  • Antiepileptic drugs
  • Epilepsy
  • GLUT1 deficiency syndrome
  • Ketogenic diet
  • Low glycemic index treatment
  • Mental retardation
  • Modified Atkins diet
  • Movement disorder
  • SLC2A1 gene
  • Triheptanoin

ASJC Scopus subject areas

  • Clinical Neurology

Cite this

Dietary treatments and new therapeutic perspective in GLUT1 deficiency syndrome. / Veggiotti, Pierangelo; De Giorgis, Valentina.

In: Current Treatment Options in Neurology, Vol. 16, No. 5, 2014.

Research output: Contribution to journalArticle

Veggiotti, Pierangelo ; De Giorgis, Valentina. / Dietary treatments and new therapeutic perspective in GLUT1 deficiency syndrome. In: Current Treatment Options in Neurology. 2014 ; Vol. 16, No. 5.
@article{eb424b423c2a4812a1a619377416a260,
title = "Dietary treatments and new therapeutic perspective in GLUT1 deficiency syndrome",
abstract = "GLUT1 deficiency syndrome (GLUT1DS) results from impaired glucose transport into the brain: awareness of its wide phenotypic spectrum is a prerequisite in order to ensure an early diagnosis, treating the patients is the subsequent challenge to allow prompt compensation for the brain's lack of fuel. The ketogenic diet (KD) plays a primary role in the treatment of GLUT1DS because it provides ketone bodies as an alternative source to meet the demands of energy of the brain. Therefore, we recommend early initiation of the KD based on the assumption that early diagnosis and treatment improves the long term neurological outcome: the classic KD (4:1 or 3:1) at the present time is the most proven and effective in GLUT1DS. A KD should be continued at least until adolescence, although there are reports of good tolerability even in adulthood, possibly with a less rigorous ratio; in our experience seizure and movement disorder control can be achieved by a 2:1 ketogenic ratio but the relationship between ketosis and neurodevelopmental outcome remains undetermined. Other types of KDs can, therefore, be considered. The Modified Atkins diet, for example, is also well tolerated and provides effective symptom control; furthermore, this diet has the advantage of being easy to prepare and more palatable, which are important requirements for good compliance. Nevertheless, about 20 {\%} of these patients have compliance trouble or the same diet loses its effectiveness over time; for these reasons, new therapeutic strategies are currently under investigation but further studies on pathophysiological mechanisms and potential effects of novel {"}diets{"} or {"}therapies{"} are needed for this new pathology.",
keywords = "Antiepileptic drugs, Epilepsy, GLUT1 deficiency syndrome, Ketogenic diet, Low glycemic index treatment, Mental retardation, Modified Atkins diet, Movement disorder, SLC2A1 gene, Triheptanoin",
author = "Pierangelo Veggiotti and {De Giorgis}, Valentina",
year = "2014",
doi = "10.1007/s11940-014-0291-8",
language = "English",
volume = "16",
journal = "Current Treatment Options in Neurology",
issn = "1092-8480",
publisher = "Current Science, Inc.",
number = "5",

}

TY - JOUR

T1 - Dietary treatments and new therapeutic perspective in GLUT1 deficiency syndrome

AU - Veggiotti, Pierangelo

AU - De Giorgis, Valentina

PY - 2014

Y1 - 2014

N2 - GLUT1 deficiency syndrome (GLUT1DS) results from impaired glucose transport into the brain: awareness of its wide phenotypic spectrum is a prerequisite in order to ensure an early diagnosis, treating the patients is the subsequent challenge to allow prompt compensation for the brain's lack of fuel. The ketogenic diet (KD) plays a primary role in the treatment of GLUT1DS because it provides ketone bodies as an alternative source to meet the demands of energy of the brain. Therefore, we recommend early initiation of the KD based on the assumption that early diagnosis and treatment improves the long term neurological outcome: the classic KD (4:1 or 3:1) at the present time is the most proven and effective in GLUT1DS. A KD should be continued at least until adolescence, although there are reports of good tolerability even in adulthood, possibly with a less rigorous ratio; in our experience seizure and movement disorder control can be achieved by a 2:1 ketogenic ratio but the relationship between ketosis and neurodevelopmental outcome remains undetermined. Other types of KDs can, therefore, be considered. The Modified Atkins diet, for example, is also well tolerated and provides effective symptom control; furthermore, this diet has the advantage of being easy to prepare and more palatable, which are important requirements for good compliance. Nevertheless, about 20 % of these patients have compliance trouble or the same diet loses its effectiveness over time; for these reasons, new therapeutic strategies are currently under investigation but further studies on pathophysiological mechanisms and potential effects of novel "diets" or "therapies" are needed for this new pathology.

AB - GLUT1 deficiency syndrome (GLUT1DS) results from impaired glucose transport into the brain: awareness of its wide phenotypic spectrum is a prerequisite in order to ensure an early diagnosis, treating the patients is the subsequent challenge to allow prompt compensation for the brain's lack of fuel. The ketogenic diet (KD) plays a primary role in the treatment of GLUT1DS because it provides ketone bodies as an alternative source to meet the demands of energy of the brain. Therefore, we recommend early initiation of the KD based on the assumption that early diagnosis and treatment improves the long term neurological outcome: the classic KD (4:1 or 3:1) at the present time is the most proven and effective in GLUT1DS. A KD should be continued at least until adolescence, although there are reports of good tolerability even in adulthood, possibly with a less rigorous ratio; in our experience seizure and movement disorder control can be achieved by a 2:1 ketogenic ratio but the relationship between ketosis and neurodevelopmental outcome remains undetermined. Other types of KDs can, therefore, be considered. The Modified Atkins diet, for example, is also well tolerated and provides effective symptom control; furthermore, this diet has the advantage of being easy to prepare and more palatable, which are important requirements for good compliance. Nevertheless, about 20 % of these patients have compliance trouble or the same diet loses its effectiveness over time; for these reasons, new therapeutic strategies are currently under investigation but further studies on pathophysiological mechanisms and potential effects of novel "diets" or "therapies" are needed for this new pathology.

KW - Antiepileptic drugs

KW - Epilepsy

KW - GLUT1 deficiency syndrome

KW - Ketogenic diet

KW - Low glycemic index treatment

KW - Mental retardation

KW - Modified Atkins diet

KW - Movement disorder

KW - SLC2A1 gene

KW - Triheptanoin

UR - http://www.scopus.com/inward/record.url?scp=84899091851&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84899091851&partnerID=8YFLogxK

U2 - 10.1007/s11940-014-0291-8

DO - 10.1007/s11940-014-0291-8

M3 - Article

AN - SCOPUS:84899091851

VL - 16

JO - Current Treatment Options in Neurology

JF - Current Treatment Options in Neurology

SN - 1092-8480

IS - 5

ER -